Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
Mariarosaria Saponaro(University of Naples Federico II), Grazia Arpino(University of Naples Federico II), Antonella Turla(University of Brescia), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmine De Angelis(Baylor College of Medicine), Filippo Montemurro(Roche (Switzerland)), Luigi Annunziata(University of Naples Federico II), Ilaria Viganò(Ospedale Valduce), Mario Giuliano(Regione Campania), Lucia Del Mastro(Ospedale Policlinico San Martino), Francesco Schettini(Target (United States)), Giuseppe Buono(Federico II University Hospital), Fabio Puglisi(University of Udine)
Cited by 7
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751